# Neuregen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuregen

- Industry: Healthcare
- Headquarters: Suzhou, China
- Total disclosed funding: $15M
- Latest round: Series A (May 21, 2026)
- Investors on record: 3

## About

Based in Suzhou, China and founded in 2021, Neuregen Biomedical Technology (Suzhou) Co., Ltd., dba Neuregen, is a company that develops gene therapy drugs, focusing on drug development using cell transdifferentiation technology and genetic replacement technology with its own intellectual property rights. The company's core team members have experience in in-situ transdifferentiation technology and gene therapy research and come from the Chinese Academy of Sciences, Peking Union Medical College and other institutions. In 2023, the company was honored with awards such as China's Front-Runners (Front-Runners) Top 100 in biopharmaceuticals. In May 2026, Neuregen closed nearly CNY 100 million in Series A led by Wuhan High-tech Industry Investment Private Fund Management, with participation from SB China Venture Capital.

The company has established a gene therapy drug R&D platform based on in-situ cellular transdifferentiation technology with independent intellectual property rights, including screening of transdifferentiation factors, design of viral and non-viral vectors, and development of in-vivo and ex-vivo pharmacodynamic methods. Its current product pipeline focuses on neurological diseases, with an emphasis on blinding eye diseases and difficult-to-treat neurological tumors, and extends to major neurodegenerative diseases.

The company generates revenue from developing novel gene therapy drugs.

## Funding rounds

- Series A, May 21, 2026, $15M — SB China Venture Capital, Wuhan High-tech Industry Investment Private Fund Management
- Angel, Feb 15, 2022 — GSR United Capital

## Investors

- GSR United Capital (https://capitalatlas.ai/funds/gsr-united-capital) — Angel
- SB China Venture Capital (https://capitalatlas.ai/funds/sb-china-venture-capital) — Series A
- Wuhan High-tech Industry Investment Private Fund Management (https://capitalatlas.ai/funds/wuhan-high-tech-industry-investment-private-fund-management) — Series A